Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Differentiated Thyroid Cancer 2Colorectal Neoplasms 2Stomach Neoplasms 1Solid Tumor 1Nasopharyngeal Carcinoma 1Leukemia, Myeloid, Acute 1Esophageal Neoplasms 1Advanced Solid Tumor 1

Interventions

Capecitabine 77pembrolizumab 71Oxaliplatin 68Cisplatin 56Fluorouracil 52Paclitaxel 41Trastuzumab 37Nivolumab 35Leucovorin 27Docetaxel 27Irinotecan 22Ramucirumab 20Gemcitabine 15Bevacizumab 15S 1 (combination) 14Carboplatin 13atezolizumab 12apatinib 12fludarabine 11Cyclophosphamide 11tislelizumab 10Drug Therapy 10Injections 8130-nm albumin-bound paclitaxel 8trastuzumab deruxtecan 7durvalumab 7Ipilimumab 7Folfox protocol 7Albumin-Bound Paclitaxel 7titanium silicide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Stomach Neoplasms × donafenib × Clear all
NCT02489214 2023-05-08

Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Terminated
13 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡